Ningbo Menovo Pharmaceutical Co., Ltd. Class A

Ningbo Menovo Pharmaceutical Co., Ltd. Class A

SSSE:603538
19.14
CNY
-0.43
(-2.20%)
0.34EPS
83.11P/E
9.72BMarket Cap
Apr 22Next Earn

Total Valuation

CNY

As of September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A carries a market capitalization of 9.72B, placing it among publicly traded companies globally. Its enterprise value stands at 10.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap9.72B
Enterprise Value10.02B

Important Dates

Ningbo Menovo Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 22, 2027.

Earnings Date4/22/2027

Share Statistics

As of September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A has 339.93M shares outstanding.

Shares Outstanding339.93M

Valuation Ratios

As of September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 83.11. The price-to-sales ratio is 5.02, and the price-to-book ratio stands at 3.31.

PE Ratio83.11
PS Ratio5.02
PB Ratio3.31
P/TBV Ratio3.60

Enterprise Valuation

As of September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 67.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 67.11 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 10.02B versus a market cap of 9.72B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.49
EV / EBITDA67.11
EV / EBIT67.11

Financial Position

As of September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.11, indicating elevated leverage, while an interest coverage ratio of 11.46 demonstrates strong ability to service its debt obligations.

Current Ratio1.37
Quick Ratio0.36
Debt / Equity26.11
Debt / EBITDA5.30
Interest Coverage11.46

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 770,900.79 in revenue per employee across its workforce of 2,370.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee770,900.79
Employee Count2,370.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A recorded 34.79M in income tax expense. That works out to an effective tax rate of 23.88, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 145.70M, leaving 110.43M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax34.79M
Effective Tax Rate23.88

Stock Price Statistics

CNY

As of the close on November 17, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A's stock has gained approximately 20.92% over the past 52 weeks. The 50-day moving average sits at 24.14, while the 200-day moving average is 26.54.

52-Week Price Change20.92%
50-Day Moving Average24.14
200-Day Moving Average26.54

Income Statement

CNY

Over the twelve months ended September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A generated 1.83B in revenue and converted that into 110.43M in net income, yielding earnings per share of 0.34. EBITDA reached 149.37M, while operating income came in at 222.29M.

Revenue1.83B
Gross Profit551.71M
Operating Income222.29M
Pretax Income145.70M
Net Income110.43M
EBITDA149.37M
EBIT149.37M
Earnings Per Share (EPS)0.34

Balance Sheet

CNY

As of September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A holds 579.72M in cash and equivalents against 791.40M in total debt, resulting in a net debt position of 202.55M. Total book value stands at 2.94B, with working capital of 593.37M providing operational flexibility.

Cash & Cash Equivalents579.72M
Total Debt791.40M
Net Debt202.55M
Equity (Book Value)2.94B
Book Value Per Share8.64
Working Capital593.37M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-149.40M

Margins

Over the twelve months ended September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A posted a gross margin of 30.20, reflecting its pricing power and cost economics. The operating margin of 12.17 and net profit margin of 6.04 provide insight into operational efficiency.

Gross Margin30.20
Operating Margin12.17
Pretax Margin7.97
Profit Margin6.04
EBITDA Margin8.18

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A paid dividends of 0.04 per share. The dividend payout ratio of 10.24 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.90, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ningbo Menovo Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.04
Payout Ratio10.24
Shareholder Yield1.90

Stock Splits

Ningbo Menovo Pharmaceutical Co., Ltd. Class A's most recent stock split took place on July 9, 2026 with a 5:7 split ratio.

Last Split Date7/9/2026
Split Ratio5:7

Scores

As of September 30, 2026, Ningbo Menovo Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 4.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.49